期刊首页 优先出版 当期阅读 过刊浏览 作者中心 关于期刊 English

《工程(英文)》 >> 2020年 第6卷 第10期 doi: 10.1016/j.eng.2020.10.003

中国抗击新型冠状病毒的策略与进展

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China

收稿日期: 2020-10-04 修回日期: 2020-10-05 录用日期: 2020-10-09 发布日期: 2020-10-15

下一篇 上一篇

摘要

新型冠状病毒肺炎(COVID-19)是21世纪第三次由冠状病毒引发的流行病,并导致全球大规模感染和死亡,造成全球性公共卫生事件。基于在防控重症急性呼吸综合征(SARS)和中东呼吸综合征(MERS)两次疫情中积累的经验,中国迅速确定病毒传播途径,总结临床特点,提出治疗干预措施并开展疫苗研发,在科学界发挥了关键作用。尽管针对COVID-19的研究取得了快速进展,但在追溯病毒起源、明确传播途径和解析致病机制等方面仍有待进一步研究。目前仍需建立更具针对性的临床治疗方案以及研发特效药。本文总结了中国针对COVID-19防控的主要策略及研究进展,以期为全球疫情防控提供有用的信息。

参考文献

[ 1 ] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74. 链接1

[ 2 ] Brielle ES, Schneidman-Duhovny D, Linial M. The SARS-CoV-2 exerts a distinctive strategy for interacting with the ACE2 human receptor. Viruses 2020;12(5):497. 链接1

[ 3 ] Hu T, Liu Y, Zhao M, Zhuang Q, Xu L, He Q. A comparison of COVID-19, SARS and MERS. Peer J 2020;8:e9725. 链接1

[ 4 ] Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24 (6):490–502. 链接1

[ 5 ] Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866 (10):165878. 链接1

[ 6 ] Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 2020;296(2):E15–25. 链接1

[ 7 ] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. 链接1

[ 8 ] Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect 2020;81 (1):1–9. 链接1

[ 9 ] Lai S, Ruktanonchai NW, Zhou L, Prosper O, Luo W, Floyd JR, et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. Nature 2020;585:410–3. 链接1

[10] Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924. 链接1

[11] Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91–8. 链接1

[12] Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372. 链接1

[13] Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA 2020;117(13):7001–3. 链接1

[14] Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26:1017–32. 链接1

[15] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID19. N Engl J Med 2020;383:120–8. 链接1

[16] Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1446. 链接1

[17] Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol 2020;215:108448. 链接1

[18] Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and immunologic variations associated with the progression of 链接1

[19] Anand SP, Chen Y, Prévost J, Gasser R, Beaudoin-Bussières G, Abrams CF, et al. Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV2 S glycoproteins. Viruses 2020;12(10):1104. 链接1

[20] Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective. J Allergy Clin Immunol 2020;146 (2):285–99. 链接1

[21] Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020;181(4). 894–904. E9. 链接1

[22] Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177–9. 链接1

[23] Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARSCoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 2020;182(2). 429–46.E14. 链接1

[24] Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F, Koonin EV. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci USA 2020;117(26):15193–9. 链接1

[25] Kim SJ, Nguyen VG, Park YH, Park BK, Chung HC. A novel synonymous mutation of SARS-CoV-2: is this possible to affect their antigenicity and immunogenicity? Vaccines 2020;8(2):220. 链接1

[26] Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis 2020;96:459–60. 链接1

[27] Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens 2020;9(5):324. 链接1

[28] Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ 2020;98:495–504. 链接1

[29] Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 2020;183(3):739–51.e8.

[30] Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323(18):1843–4. 链接1

[31] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–36. 链接1

[32] Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386–9. 链接1

[33] Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5 (5):434–5. 链接1

[34] Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158(6). 1831–3.E3. 链接1

[35] Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020;69(6):997–1001. 链接1

[36] Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020; 115(5):766–73. 链接1

[37] Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020;55(47):eabc3582. 链接1

[38] Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerging Infect Dis 2020;26(8):1920–2. 链接1

[39] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. 链接1

[40] Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection—challenges and implications. N Engl J Med 2020;383:e38. 链接1

[41] Li Z, Li Y, Chen L, Li S, Yu L, Zhu A, et al. A confirmed case of SARS-CoV-2 pneumonia with negative routine reverse transcriptasepolymerase chain reaction and virus variation in Guangzhou, China. Clin Infect Dis. In press..

[42] Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol 2020;58(6). e00461–20. 链接1

[43] Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med 2020;58 (7):1037–52. 链接1

[44] Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detection and dynamic characteristics in patients with coronavirus disease 2019. Clin Infect Dis 2020;71(8):1930–4.

[45] Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020;9(1):940–8. 链接1

[46] Ren L, Fan G, Wu W, Guo L, Wang Y, Li X, et al. Antibody responses and clinical outcomes in adults hospitalized with severe COVID-19: a post hoc analysis of LOTUS China Trial. Clin Infect Dis. In press..

[47] Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 2020;181(4). 865–76.E12. 链接1

[48] Wang X, Zhong M, Liu Y, Ma P, Dang L, Meng Q, et al. Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-based detection with naked eye readout, CRISPR/Cas12a-NER. Sci Bull 2020;65(17):1436–9. 链接1

[49] Xiang X, Qian K, Zhang Z, Lin F, Xie Y, Liu Y, et al. CRISPR-Cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia. J Drug Target 2020;28(7– 8):727–31. 链接1

[50] Ackerman CM, Myhrvold C, Thakku SG, Freije CA, Metsky HC, Yang DK, et al. Massively multiplexed nucleic acid detection with Cas13. Nature 2020;582:277–82. 链接1

[51] Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPRCas12-based detection of SARS-CoV-2. Nat Biotechnol 2020;38:870–4. 链接1

[52] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. 链接1

[53] Chen L, Li Q, Zheng D, Jiang H, Wei Y, Zou L, et al. Clinical characteristics of pregnant women with COVID-19 in Wuhan, China. N Engl J Med 2020;382: e100. 链接1

[54] Mofenson LM, Ciaranello A, LaHood N. More on clinical characteristics of pregnant women with COVID-19 in Wuhan, China. N Engl J Med 2020;383:696–703. 链接1

[55] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):2000547. 链接1

[56] Alanazi KH, Abedi GR, Midgley CM, Alkhamis A, Alsaqer T, Almoaddi A, et al. Diabetes mellitus, hypertension, and death among 32 patients with MERSCoV infection. Saudi Arabia Emerg Infect Dis 2020;26(1):166–8. 链接1

[57] Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. JAMA 2003;289(21):2801–9. 链接1

[58] Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. In press..

[59] Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2:1069–76. 链接1

[60] Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of COVID-19. N Engl J Med 2020;382:2441–8. 链接1

[61] Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med 2020;382:e102. 链接1

[62] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin– aldosterone system blockers and the risk of COVID-19. N Engl J Med 2020;382:2431–40. 链接1

[63] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARSCoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21 (3):335–7. 链接1

[64] Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery 2020;10(6):783–91. 链接1

[65] Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med 2020;173:362–7. 链接1

[66] Day M. COVID-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 2020;369:m1375. 链接1

[67] Wang Y, Tong J, Qin Y, Xie T, Li J, Li J, et al. Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, China. Clin Infect Dis. In press..

[68] Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect 2020;26(7). 948e1–3. 链接1

[69] Li W, Su YY, Zhi SS, Huang J, Zhuang CL, Bai WZ, et al. Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol Infect 2020;26(11):1556.e1–e6.

[70] Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. Clin Infect Dis. In press..

[71] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42. 链接1

[72] Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180(8):1081–9. 链接1

[73] Liang W, Yao J, Chen A, Lv Q, Zanin M, Liu J, et al. Early triage of critically ill COVID-19 patients using deep learning. Nat Commun 2020;11:3543. 链接1

[74] Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID19 pneumonia using computed tomography. Cell 2020;181(6). 1423–33.E11. 链接1

[75] Mei X, Lee HC, Diao KY, Huang M, Lin B, Liu C, et al. Artificial intelligenceenabled rapid diagnosis of patients with COVID-19. Nat Med 2020;26:1224–8. 链接1

[76] Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X, et al. Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID19 pneumonia using computed tomography. Cell 2020;182(5):1360. 链接1

[77] Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020;9:940–8. 链接1

[78] Song JC, Wang G, Zhang W, Zhang Y, Li WQ, Zhou Z, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID19. Mil Med Res 2020;7:19. 链接1

[79] Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020;395(10235):1517–20. 链接1

[80] Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31(1):69–75. 链接1

[81] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71. 链接1

[82] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir– ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787–99. 链接1

[83] Yan D, Liu XY, Zhu YN, Huang L, Dan BT, Zhang GJ, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J 2020;56:2000799. 链接1

[84] Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849. 链接1

[85] Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569–78. 链接1

[86] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—preliminary report. N Engl J Med 2020;383:992–4. 链接1

[87] Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395(10238):1695–704. 链接1

[88] Huang M, Li M, Xiao F, Pang P, Liang J, Tang T, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev 2020;7(9):1428–36. 链接1

[89] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. In press..

[90] Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis 2020;20(4):410–1. 链接1

[91] Cheng LL, Guan WJ, Duan CY, Zhang NF, Lei CL, Hu Y, et al. Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: a randomized clinical trial. JAMA Intern Med. In press..

[92] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180 (7):934–43. 链接1

[93] The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19preliminary report. N Engl J Med. In press..

[94] The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324(13):1330–41. 链接1

[95] Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323 (16):1582–9. 链接1

[96] Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324 (5):460–70. 链接1

[97] Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends 2020;14(4):285–9. 链接1

[98] Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 2020;190(1):e24–7. 链接1

[99] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844–7. 链接1

[100] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–9. 链接1

[101] Kiyota T, Shiota S, Hamanaka R, Tsutsumi D, Takakura T, Miyazaki E. Diffuse alveolar hemorrhage caused by warfarin after rifampicin discontinuation. Case Rep Med 2019;2019:4917856. 链接1

[102] Kneyber MC, van Heerde M, Twisk JW, Plotz FB, Markhors DG. Heliox reduces respiratory system resistance in respiratory syncytial virus induced respiratory failure. Crit Care 2009;13:R71. 链接1

[103] Jolliet P, Ouanes-Besbes L, Abroug F, Ben Khelil J, Besbes M, Garnero A, et al. A multicenter randomized trial assessing the efficacy of helium/oxygen in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;195(7):871–80. 链接1

[104] Zhou ZQ, Zhong CH, Su ZQ, Li XY, Chen Y, Chen XB, et al. Breathing hydrogen– oxygen mixture decreases inspiratory effort in patients with tracheal stenosis. Respiration 2019;97(1):42–51. 链接1

[105] Guan WJ, Wei CH, Chen AL, Sun XC, Guo GY, Zou X, et al. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J Thorac Dis 2020;12(6):3448–52. 链接1

[106] National Health Commission of the People’s Republic of China; National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7) [Internet]. Beijing: The State Council of the People’s Republic of China; c2020 [cited 2020 Sep 5]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a 7dfe4cef80dc7f5912eb1989.shtml?spm=C73544894212.P59511941341.0.0. Chinese. 链接1

[107] Liu M, Ya G, Yuan Y, Yang K, Shi S, Tian J, et al. Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis. Integr Med Res 2021;10(1):100644. 链接1

[108] Khan S, Ali A, Shi H, Siddique R, Shabana Nabi G, et al. COVID-19: clinical aspects and therapeutics responses. Saudi Pharm J 2020;28(8):1004–8. 链接1

[109] Li R, Hou Y, Huang J, Pan W, Ma Q, Shi Y, et al. Lianhuaqingwen exerts antiviral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761. 链接1

[110] Hu K, Guan W, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. In press..

[111] Sun J, Zhuang Z, Zheng J, Li K, Wong RL, Liu D, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 2020;182(3). 734–43.E5. 链接1

[112] Wen L, Zhou Z, Jiang D, Huang K. Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019. Chin Crit Care Med 2020;32(4):426–9. Chinese. 链接1

[113] Kutsuna S, Asai Y, Matsunaga A. Loss of anti-SARS-CoV-2 antibodies in mild COVID-19. N Engl J Med 2020;383(17):1695–6. 链接1

[114] Draft landscape of COVID-19 candidate vaccines [Internet]. Geneva: World Health Organization; 2020 Oct 2 [cited 2020 Sep 20]. Available from: https:// www.who.int/publications/m/item/draft-landscape-of-covid-19-candidatevaccines. 链接1

[115] Four Chinese COVID-19 vaccines undergoing phase-3 clinical trials [Internet]. Beijing: China Daily; c1995–2020 [updated 2020 Aug 29; cited 2020 Sep 20]. Available from: www.chinadaily.com.cn/a/202008/29/WS5f49e230a310675 eafc56454.html. 链接1

[116] cde.org.cn [Internet]. Beijing: Centre for Drug Evaluation, National Medical Products Administration; [cited 2020 Sep 20]. Available from: www.cde.org. cn. Chinese. 链接1

[117] Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020;182 (3). 722–33.E11. 链接1

[118] Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369(6499): 77–81. 链接1

[119] Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020;324(10): 951–60. 链接1

[120] Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020;586:572–7.

[121] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet 2020;396(10249):479–88. 链接1

[122] clinicaltrials.gov [Internet]. Bethesda: National Library of Medicine; [cited 2020 Sep 20]. Available from: https://www.clinicaltrials.gov/. 链接1

[123] chictr.org.cn [Internet]. Shenzhen: Chinese Clinical Trail Registry; c2005– 2015 [cited 2020 Sep 20]. Available from: www.chictr.org.cn. Chinese. 链接1

[124] Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2preliminary report. N Engl J Med 2020;383:1920–31.

[125] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARSCoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396(10249):467–78. 链接1

[126] Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020;11:4081. 链接1

相关研究